Allergan Pharmaceuticals International Ltd., a subsidiary of AbbVie, Inc., is a company headquartered in Ireland. The firm provides legal services.

Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen has developed a synthetic version of the elastin protein which is identical to that naturally present in the human body. Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair. Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups. Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.

DelSite, Inc. research-based, biopharmaceutical and consumer products company with a core technology based on naturally occurring complex carbohydrates.\nDelSite is developing its proprietary GelSite technology designed to provide controlled release of peptide and protein-based drugs. More than 130 patents protect its technology.\nIt was incorporated in Texas in 1973, as Carrington Laboratories, Inc.

Hadasit is the technology transfer company of Hadassah Medical Center in Jerusalem. They transform the cutting-edge research coming out of Hadassah into marketable medical technologies. They turn ground-breaking ideas into viable products and services that can change the world and better humanity. For more than a century, Hadassah has set the standard of excellence for medical care and research in Israel. Their doctors and scientists are on the frontlines, uniquely positioned to pinpoint ever-evolving medical needs. Their experience and ingenuity has yielded new ideas with huge potential in all areas of medicine, including therapeutics, diagnostic medical devices, and digital health. More than half of all hospital research in Israel is conducted at Hadassah. Hadasit is Hadassah’s vehicle for commercialization of the intellectual property and R&D capabilities developed there. Hadasit holds exclusive rights to every innovation and invention emerging from Hadassah and they are dedicated to bringing these life-saving technologies to the general public.

Anterogen Co., Ltd. engages in the development and sale of stem cell therapy treatments. Its products include Cupistem and Remodullin injection, Queencell, and stem cell conditioned media. It also offers stem cell banking and analysis services. The company was founded on March 16, 2000 and is headquartered in Seoul, South Korea.

Johnson & Johnson Consumer, Inc. manufactures health and skin care products. It offers wide variety of lotion, moisturizing cream, baby wash, shampoo and conditioner, baby powder and bath, hand and face wipes, soap, baby oil and cologne. The company was founded on March 8, 2016 and is headquartered in Skillman, NJ.

SIFI is a leading player in the Italian ophthalmic industry. The company develops, manufactures and sells pharmaceutical treatments, diagnostic instruments and surgical equipment for eyecare, covering the vast majority of ocular pathologies.

Opocrin SpA engages in the manufacture and marketing of active ingredients for the pharmaceutical industry. Its products include Collagen Gel, Sodium and Calcium Heparin, Iron Complexes, Parnaparin, and Pulmonary Surfactant. The company was founded by Pietro Bianchini in 1964 and is headquartered in Modena, Italy.

Lipotec is a well-known worldwide expert in advanced active ingredients for application in cosmetics. As Lubrizol’s Global Center of Expertise for Skin Care, Lipotec™ Active Ingredients researches, develops and produces innovative products – from peptides, biotechnological molecules to botanical extracts and delivery systems. The most known example of their expertise is ARGIRELINE® peptide, the first topical alternative to recognized cosmetic procedures against expression wrinkles.

Procare Health is engaged in women’s health. They have launched innovative products on the market, formulated with bio-optimized ingredients of natural origin, which have revolutionized the of life of women around the world. They provide medicine for osteoporosis, arthrosis, intimate health, and HIV.

The USC Incubator accelerates the development of USC’s top student and alumni entrepreneurs through experiential education, mentorship and community. The USC Incubator, supported by the Greif Center for Entrepreneurial Studies at USC’s Marshall School takes founders from feasibility and development work, on to customers, a tested business model, getting distribution, building a team, bootstrapping and investment preparation. They also provide access to other supporting resources, such as legal and financial assistance.

Nanotherapeutics is a privately held specialty biopharmaceutical company with full product development, cGMP manufacturing capabilities, and a proprietary pipeline. The Company's technologies can be used with all drug types ranging from small molecules to proteins and peptides. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.

Part of Sanofi, Mendes is a French company located in Houilles focused on apparel and accessories. Sanofi acquired Mendes on July 01, 1998.

Vicus Therapeutics is an immuno-oncology company. Using a rational data-driven discovery process, Vicus transforms FDA-approved drugs into Precision Medicines to damp tumor promoting inflammation, restore immune surveillance and improve treatment tolerance. Its products are in front of two trends simultaneously occurring in the oncology marketplace: the emergence of Immunotherapy to treat cancer and the transition to Precision Medicines that target the right patients with the right drugs at the right doses as the right times. Vicus lead drug, VT-122, is the 1st multi-pathway neuro-immune modulator for the treatment of cancer. VT-122 is a chrono-formulation of etodolac and propranolol that modulate beta adrenergic receptors 1-2, COX-2 enzyme &TRPA1 channel, and the MAPK, PI3K, PKA, AKT and nociception signaling cascades. VT-122 unique MOA, safety and efficacy profile is supported by over one hundred published animal and human studies of its components and component classes across tumor types. VT-122 recently recently completed a Phase 2 study of advanced liver cancer patients receiving sorafenib and investigator-initiated studies of liver, pancreatic and brain cancers. These studies show VT-122 increased median overall survival 4 to 7 months versus standard of care alone and reduced toxicities with no treatment related SAEs. VT-122 has been granted US FDA Orphan Drug designations for the treatment of pancreatic, liver and brain cancers.